IN8bio presents data on DeltEx Allo manufacturing program

IN8bio (INAB) announced new data on its proprietary gammadelta T manufacturing program. The oral presentation shared exciting updates about its unique manufacturing processes, including deep analytics, genomics and repertoire analysis, presented at the International Society for Cell & Gene Therapy 2025 Annual Meeting. The data, which earned IN8bio the prestigious Host Region Abstract Award, as presented by Bruce Levine, PhD, ISCT Past President and a member of IN8bio’s Scientific Advisory Board. The award is a competitive recognition for scientific excellence and demonstrates how IN8bio’s technology and know-how creates consistent, powerful cellular therapies. The oral presentation highlights how IN8bio’s DeltEx Allo manufacturing process consistently induces donor derived T cells to express gammadelta T cell receptors and genes, associated with increased cancer cytotoxicity. Gene expression profiling confirmed a highly potent product across multiple manufacturing batches. Key Findings from the INB-100 Study Presented at ISCT: Manufacturing-Driven TCR Reprogramming: All analyzed clinical batches showed a clear and consistent shift from alphabeta-TCR to gammadelta-TCR dominance, with enrichment of Vgamma9 clones. This shift occurred independent of donor starting material, indicating the process-not the donor-drives final TCR composition. Uniform Potency Markers Across Donors: All manufactured clinical products showed high expression levels of genes linked to increased cancer killing, immune activation, and tumor seeking migration. Durable Remissions in AML Patients: All 10 patients in the initial cohort remained relapse-free for more than one year, with a median overall survival of 23.3 months as of January 2024. These results highlight the strength and reproducibility of IN8bio’s cell therapy manufacturing processes. These products were administered clinically in the INB-100 clinical trial, which has demonstrated durable long-term remissions in adult AML patients with high-risk, complex disease characteristics. Further, long term expansion and persistence of the gammadelta T cells have been observed in these patients through 1 year, a first for an allogeneic cellular therapy product. IN8bio’s manufacturing program has been automated, enabling rapid and reproducible production of cryopreserved cell therapy doses. The INB-100 trial continues to enroll an expansion cohort at the recommended Phase 2 dose.